Maxillary Sinus Sarcomas: Epidemiological and Clinicopathological Experience of 25 Years in a National Reference Cancer Center

Salcedo-Hernández, Rosa Angélica; Lino-Silva, Leonardo S.; Luna-Ortiz, Kuauhyama

doi:10.1007/s12070-012-0522-9

Cited by 10 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While each of the markers can occasionally be seen in SS, the combined co-expression of S100, actin, β-catenin, and in some cases, desmin and myogenin strongly favor BSNS over SS. It is also important to note that SS is extremely rare in the sinonasal tract, with only ten reported cases overall[35–37], just two of which have molecular confirmation. Moreover, as noted above, at least one case of sinonasal synovial sarcoma (from our institution) [38] was subsequently revealed to be BSNS.…”

Section: Discussionmentioning

confidence: 99%

Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

et al. 2016

View full text Add to dashboard Cite

Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized low-grade sarcoma that exhibits both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment along both lineages. While identification of PAX3 rearrangements by fluorescence in situ hybridization (FISH) can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate recognition of BSNS without molecular analysis. Eleven cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 8 cases, the diagnosis was confirmed by FISH using custom probes for PAX3. In 3 cases FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. All 11 BSNS (100%) were at least focally positive for S100 as well as calponin and/or smooth muscle actin. In addition, 10 of 11 (91%) expressed nuclear β-catenin, 8 of 10 (80%) expressed factor XIIIa, 4 of 11 (36%) expressed desmin, and 3 of 10 (30%) expressed myogenin. All 11 tumors were negative for SOX10. While no single marker resolves immunohistochemical overlap between BSNS and its histologic mimickers such as nerve sheath tumors, an extended immunohistochemical panel that includes β-catenin and SOX10 helps to support the diagnosis of BSNS without the need for gene rearrangement studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It may present with nasal obstruction, pain, earache, sore throat, epistaxis, and rarely diplopia or vision loss. 5 A CT scan can indicate the malignant nature of the nasal mass, but an endoscopic biopsy is confirmatory for this rare tumor. It is treated by surgery followed by chemoradiation.…”

Section: Discussionmentioning

confidence: 97%

“…Hereditary retinoblastoma, neuroblastoma, and Lynch syndrome are a predisposing factor for the development of sarcomas. 5 It contributes 8 to 10% in soft tissue sarcomas, whereas out of these, 5 to 10% occur in the head and neck region. 2 6 It has been found in almost all locations of the head and neck region, but its occurrence in the paranasal sinus is rare.…”

Section: Discussionmentioning

confidence: 99%

“… 2 6 It has been found in almost all locations of the head and neck region, but its occurrence in the paranasal sinus is rare. 5 7 8 Further, ethmoidal sinus synovial sarcoma is rarer as only three cases has been reported till date.…”

Section: Discussionmentioning

confidence: 99%

“…It may present with nasal obstruction, pain, earache, sore throat, epistaxis, and rarely diplopia or vision loss. 5 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Synovial Sarcoma of Ethmoidal Sinus

et al. 2021

View full text Add to dashboard Cite

Background Synovial sarcoma is an aggressive soft tissue cancer of extremities mainly and rare in head and neck region, whereas rarest in ethmoidal sinus as only three cases have been reported till date. Case Reports We managed two cases of synovial sarcoma who presented with nasal obstruction, epistaxis, and swelling around the nasofacial region. Endoscopic nasal biopsy and immunohistochemistry markers confirmed synovial sarcoma in both the cases. While one case was managed by surgery and chemoradiation, the second patient received two cycles of ifosfamide-based chemotherapy and succumbed after 6 weeks of diagnosis. Conclusion Head and neck sarcomas are aggressive and carry a poor prognosis. Surgical resection with postoperative radiotherapy is the standard treatment. However, they have a high risk of recurrence and hence aggressive management and close follow-up is warranted for the optimal outcome.

show abstract

Head and neck sarcomas: Thirty years of experience in a tertiary referral center in Brazil

Cattan,

Kimura,

Lavareze

et al. 2024

Head & Neck

View full text Add to dashboard Cite

PurposeThis study analyzed the demographics, clinicopathological, treatment, and survival characteristics of head and neck sarcomas (HNS) diagnosed in a tertiary reference center in Brazil.Materials and methodsHNS cases were retrospectively retrieved from the Department of Pathological Anatomy of the School of Medical Sciences of the State University of Campinas. The medical records were examined to extract demographic, clinicopathological, and follow‐up information. The Pearson chi‐square test, Kaplan–Meier curve, and Cox proportional hazards regression model were employed to identify survival and potential prognostic factors.ResultsA total of 47 patients were included in the study. The majority were men (61.7%) with a mean age of 38.9 years. The nasal cavity (34.0%) was the most common anatomical site. The lesions are usually presented as volume increases (78.7%). The most common histological subtypes were chondrosarcoma, osteosarcoma, and alveolar rhabdomyosarcoma. Surgical excision alone was the most common treatment modality. Local recurrence was observed in 10 cases, and metastases in 3 cases. During a mean follow‐up period of 71.9 months, from diagnosis to the last follow‐up, 31 patients (65.9%) were alive without the disease. A total of 10 patients (21.3%) died of the HNS for a mean follow‐up period of 14.3 months. The time to presentation of more than 6 months (p = 0.0309) and the presence of metastases (p = 0.0315) were identified as prognostic factors for survival, while male sex was found to be an independent prognostic factor for recurrence.ConclusionIn conclusion, the results of this study indicate that the occurrence of a shorter lesion time to presentation and the presence of metastases were associated with a reduction in survival rates in patients with HNS.

show abstract

Maxillary Sinus Sarcomas: Epidemiological and Clinicopathological Experience of 25 Years in a National Reference Cancer Center

Cited by 10 publications

References 24 publications

Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression

Synovial Sarcoma of Ethmoidal Sinus

Head and neck sarcomas: Thirty years of experience in a tertiary referral center in Brazil

Contact Info

Product

Resources

About